Your browser doesn't support javascript.
loading
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Sweeney, Christopher J; Martin, Andrew J; Stockler, Martin R; Begbie, Stephen; Cheung, Leanna; Chi, Kim N; Chowdhury, Simon; Frydenberg, Mark; Horvath, Lisa G; Joshua, Anthony M; Lawrence, Nicola J; Marx, Gavin; McCaffrey, John; McDermott, Ray; McJannett, Margaret; North, Scott A; Parnis, Francis; Parulekar, Wendy; Pook, David W; Reaume, Martin Neil; Sandhu, Shahneen K; Tan, Alvin; Tan, Thean Hsiang; Thomson, Alastair; Vera-Badillo, Francisco; Williams, Scott G; Winter, Diana; Yip, Sonia; Zhang, Alison Y; Zielinski, Robert R; Davis, Ian D.
Afiliación
  • Sweeney CJ; South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, SA, Australia. Electronic address: christopher.sweeney@adelaide.edu.au.
  • Martin AJ; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
  • Stockler MR; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Concord Cancer Centre, Concord Repatriation General Hospital, Concord, NSW, Australia; Chris O'Brien Lifehouse, Sydney, NSW Australia.
  • Begbie S; Port Macquarie Base Hospital, Port Macquarie, NSW, Australia; Mid North Coast Cancer Institute, Port Macquarie, NSW, Australia.
  • Cheung L; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
  • Chi KN; BC Cancer, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada.
  • Chowdhury S; Guys and St Thomas' NHS Foundation Trust, Biomedical Research Centre, Cancer Research UK, King's College London, UK; Sarah Cannon Research Institute, London, UK.
  • Frydenberg M; Monash University, Melbourne, VIC, Australia; Australian Urology Associates, Melbourne, VIC, Australia.
  • Horvath LG; Chris O'Brien Lifehouse, Sydney, NSW Australia; University of Sydney, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, NSW, Australia.
  • Joshua AM; Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia; Garvan Institute of Medical Research, Sydney, NSW, Australia.
  • Lawrence NJ; Te Whatu Ora, Te Toka Tumai Auckland, Auckland, New Zealand; Department of Oncology, The University of Auckland, New Zealand.
  • Marx G; Sydney Adventist Hospital, Sydney, NSW, Australia; Australian National University, Canberra, ACT, Australia.
  • McCaffrey J; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland.
  • McDermott R; Cancer Trials Ireland, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; University College Dublin, Dublin, Ireland.
  • McJannett M; Australian and New Zealand Urogenital and Prostate Cancer Trials Cancer Trials Group, Camperdown, NSW, Australia.
  • North SA; Cross Cancer Institute, Edmonton, AB, Canada; University of Alberta, Edmonton, AB, Canada.
  • Parnis F; Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia; Icon Cancer Centre, Adelaide, SA, Australia.
  • Parulekar W; Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada.
  • Pook DW; Monash University, Melbourne, VIC, Australia; Monash Health, Melbourne, VIC, Australia.
  • Reaume MN; University of Ottawa, Ottawa, ON, Canada; Ottawa Hospital Research Institute, Ottawa, ON, Canada.
  • Sandhu SK; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; University of Melbourne, Melbourne, VIC, Australia.
  • Tan A; Te Whatu Ora Waikato, Hamilton, New Zealand.
  • Tan TH; Royal Adelaide Hospital, Adelaide, SA, Australia.
  • Thomson A; Royal Cornwall Hospital, Truro, UK.
  • Vera-Badillo F; Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada; Kingston Health Sciences Center, Kingston, ON, Canada.
  • Williams SG; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; University of Melbourne, Melbourne, VIC, Australia.
  • Winter D; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
  • Yip S; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
  • Zhang AY; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Chris O'Brien Lifehouse, Sydney, NSW Australia; Macquarie University, Sydney, NSW, Australia.
  • Zielinski RR; Orange Health Service, Central West Cancer Care Centre, Orange, NSW, Australia; Western Sydney University, Sydney, NSW, Australia.
  • Davis ID; Monash University, Melbourne, VIC, Australia; Eastern Health, Melbourne, VIC, Australia.
Lancet Oncol ; 24(4): 323-334, 2023 04.
Article en En | MEDLINE | ID: mdl-36990608
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Antagonistas de Andrógenos Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Aged / Humans / Male Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Antagonistas de Andrógenos Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Aged / Humans / Male Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article